Jiangsu Nhwa Pharmaceutical Co Ltd

Jiangsu Nhwa Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 5.92, indicating a robust ability to meet short-term obligations. The company's liquidity FPT (free cash flow to total debt) is favorable, supported by a free cash flow of 446,699,570 CNY and a low long-term debt of 78,335,130 CNY. The price-to-book ratio of 2.61 suggests that the company is trading at a premium to its book value, which may reflect investor confidence in its future earnings potential. In terms of profitability, the company's return on equity (ROE) of 13.12% and return on assets (ROA) of 11.46% are strong indicators of efficient capital utilization and asset management. These metrics are well above the typical thresholds for the pharmaceutical industry, suggesting that the company is outperforming its peers in generating returns for shareholders and utilizing its assets effectively. The company's revenue is primarily concentrated in its domestic market, with a significant portion derived from pharmaceutical products. While the company operates in multiple segments, the majority of its revenue is attributed to its core pharmaceutical business. The geographic exposure is largely within China, with limited international operations reported in the available data. Looking ahead, the company is expected to maintain a stable growth trajectory, with analysts forecasting a mean price target of 28.86 CNY, which is 40% higher than the current market price of 20.74 CNY. The mean recommendation of 2.00 (on a scale of 1 to 5) indicates a generally positive outlook from analysts, with one strong-buy and one hold recommendation. The company's revenue history shows consistent performance, with a net income of 1,057,334,350 CNY and operating income of 1,198,310,380 CNY, reflecting its strong operational performance. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its cash flow carefully to maintain its liquidity position. The dilution risk is low, with no significant dilution potential reported in the basic shares outstanding, which remain unchanged at 1,015,786,583. Recent events and filings indicate that the company has not issued any new shares or engaged in significant capital-raising activities in the near term. The absence of recent dilutive events supports the low dilution risk assessment. The company's capital expenditure of -437,407,150 CNY suggests that it is generating more cash than it is investing in new capital projects, which could be a sign of a mature business with stable operations.